stockrow
Friday 6 November 2026
Export LIVN’s income statement to Excel — free account
LivaNova PLC
LIVN Healthcare Medical Devices
LivaNova PLC’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 10.7% from fiscal 2024.
- Revenue
- +9.88%
- EPS
- +27.4%
- Free cash flow
- −31.0%
- Total debt
- −31.2%
Quarter to September 2026, against a year earlier
90.21
0.93
−1.02%
Follow LIVN
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
21.34 | 23.83 | 32.26 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.80 | 3.07 | 2.42 | 2.42 | |
P/FCF ratio |
31.69 | 29.69 | 21.07 | 18.94 | |
P/Operating CF |
57.20 | 67.88 | 228.44 | 40.73 | |
P/B ratio |
3.18 | 3.41 | 2.87 | 2.80 | |
Price to Tangible BV |
12.55 | 13.73 | 17.28 | 18.94 | |
EV/Sales |
2.62 | 2.92 | 2.25 | 2.23 | |
EV/EBITDA |
14.49 | 15.76 | 11.73 | 10.98 | |
EV/Operating CF |
16.61 | 17.24 | 13.13 | 12.18 | |
EV/FCF |
29.71 | 28.23 | 19.54 | 17.48 | |
Quick Ratio |
2.47 | 1.06 | 1.01 | 1.05 | |
Current Ratio |
1.74 | 1.45 | 1.33 | 1.36 | |
Net Debt/EBITDA |
0.00 | (3.07) | (4.07) | (4.10) | |
Debt/Assets |
11.02% | 11.11% | 11.44% | 14.45% | |
Debt/Equity |
0.22 | 0.22 | 0.24 | 0.31 | |
Asset Turnover |
0.57 | 0.57 | 0.56 | 0.54 | |
Operating CF/Net income |
2.15 | 0.61 | 0.68 | 2.67 | |
Capex/Depreciation |
(1.34) | (1.36) | (0.70) | (1.22) | |
Interest Coverage |
3.55 | 6.90 | 5.00 | 5.19 | |
Research and Development Expense of Revenue |
12.13% | 13.74% | 16.20% | 14.44% | |
Selling, General and Administrative Expense of Revenue |
39.40% | 40.48% | 39.63% | 39.72% | |
Intangible Assets out of Total Assets |
0.36 | 0.38 | 0.40 | 0.39 | |
Share Based Compensation of Revenue |
3.70% | 4.32% | 2.28% | 2.60% | |
Graham Net Nets |
(0.18) | (0.06) | (0.08) | (0.09) | |
Graham Number |
0.00 | 43.26 | 31.33 | 0.00 | |
Earnings Yield |
4.69% | 4.20% | 3.10% | (7.23%) | |
Free Cash Flow Yield |
3.16% | 3.37% | 4.75% | 5.28% | |
Revenue per Share |
7.13 | 7.11 | 6.62 | 6.62 | |
Operating CF per Share |
1.34 | 1.21 | 0.28 | 1.51 | |
Capex per Share |
(0.56) | (0.57) | (0.26) | (0.46) | |
Free Cash Flow per Share |
0.78 | 0.64 | 0.02 | 1.05 | |
Cash per Share |
10.23 | 9.40 | 9.87 | 11.65 | |
Shareholders Equity per Share |
24.90 | 24.11 | 22.15 | 22.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
24.90 | 24.11 | 22.15 | 22.00 | |
Free Cash Flow |
42.94 | 35.04 | 0.93 | 57.45 | |
Working Capital |
239.80 | 318.04 | 251.76 | 293.54 | |
Capital Expenditures |
(30.76) | (31.55) | (14.29) | (24.95) | |
Net Current Asset Value |
(777.60) | (290.49) | (290.79) | (304.45) | |
EV/EBIT |
24.40 | 22.91 | 16.77 | 15.53 | |
Capex to Sales |
0.08 | 0.08 | 0.04 | 0.07 | |
Price to Operating Income |
26.03 | 24.10 | 18.08 | 16.83 | |
| Other line items | |||||
Average Receivables |
223.99 | 225.75 | 215.68 | 204.57 | |
Average Payables |
97.53 | 95.16 | 93.39 | 83.44 | |
Average Inventory |
172.72 | 168.98 | 159.76 | 156.13 | |
Average Assets |
2,635.34 | 2,573.78 | 2,537.55 | 2,556.22 | |
Average Common Equity |
1,264.65 | 1,224.08 | 1,122.81 | 1,260.12 |
Columns are period end dates · fundamentals updated 5 Nov 2026